Skip to main content
Premium Trial:

Request an Annual Quote

Blackstone Appoints Savage Chair; Millennium s Grigorenko Joins NuGen Board

NEW YORK, Aug. 28 - Expression Analysis, the Research Triangle Park, NC-based gene-analysis startup, said on Aug. 26 that it had hired Wendell Jones as senior research statistician.

 

Jones will provide customized statistical planning and analysis for company clients. He was previously senior software reliability engineer at IBM.

 

Expression Analysis, which has close ties to Duke, uses Affymetrix microarrays to provide gene testing and analysis services.

 


 

Michael Savage, former CEO of Molecular Simulations, has joined the board of Blackstone Computing as chair.

 

From 1991 to 1999, Savage was chief of MSI, now known as Accelrys. He currently runs a scientific consulting business in San Diego.

 

Blackstone, based in Worcester, Mass., provides life-sciences software.

 


 

NuGen said on Aug. 19 that Millennium Pharmaceuticals microarray expert Elena Grigorenko has joined the company's advisory board.

 

At Millennium, Grigorenko leads cross-site microarray platform-evaluation efforts to improve RNA-labeling efforts. Before joining that company in 2000, she directed the microarray core facility at the Wake Forest University School of Medicine.

 

NuGen, based in San Carlos, Calif., is developing linear-amplification technology for gene expression analysis.

 



Promoted? Changing jobs? GenomeWeb wants to know. E-mail Kathleen McGowan at [email protected] to appear in PEOPLE, a roundup of personnel comings and goings in genomics, that appears every Wednesday.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.